Literature DB >> 23728340

Melanoma metastasis: new concepts and evolving paradigms.

W E Damsky1, N Theodosakis2, M Bosenberg2.   

Abstract

Melanoma progression is typically depicted as a linear and stepwise process in which metastasis occurs relatively late in disease progression. Significant evidence suggests that in a subset of melanomas, progression is much more complex and less linear in nature. Epidemiologic and experimental observations in melanoma metastasis are reviewed here and are incorporated into a comprehensive model for melanoma metastasis, which takes into account the varied natural history of melanoma formation and progression.

Entities:  

Mesh:

Year:  2013        PMID: 23728340     DOI: 10.1038/onc.2013.194

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Jann N Sarkaria; William F Elmquist
Journal:  Pharmacol Res       Date:  2017-06-17       Impact factor: 7.658

Review 2.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

3.  WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway.

Authors:  Yumei Li; Yu Zhou; Bifei Li; Fan Chen; Weiyu Shen; Yusheng Lu; Chunlian Zhong; Chen Zhang; Huanzhang Xie; Vladimir L Katanaev; Lee Jia
Journal:  Oncogene       Date:  2020-01-31       Impact factor: 9.867

4.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Authors:  Gautham Gampa; Minjee Kim; Nicholas Cook-Rostie; Janice K Laramy; Jann N Sarkaria; Linda Paradiso; Louis DePalatis; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2018-02-02       Impact factor: 3.922

Review 5.  Radiosensitizing properties of magnetic hyperthermia mediated by superparamagnetic iron oxide nanoparticles (SPIONs) on human cutaneous melanoma cell lines.

Authors:  Jakub Dalibor Rybka
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-06

6.  Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.

Authors:  Hong Jiang; Dong Ho Shin; Teresa T Nguyen; Juan Fueyo; Xuejun Fan; Verlene Henry; Caroline C Carrillo; Yanhua Yi; Marta M Alonso; Tiara L Collier; Ying Yuan; Frederick F Lang; Candelaria Gomez-Manzano
Journal:  Clin Cancer Res       Date:  2019-08-27       Impact factor: 12.531

7.  Nanoparticle-dendrimer hybrid nanocapsules for therapeutic delivery.

Authors:  Youngdo Jeong; Sung Tae Kim; Ying Jiang; Bradley Duncan; Chang Soo Kim; Krishnendu Saha; Yi-Cheun Yeh; Bo Yan; Rui Tang; Singyuk Hou; Chaekyu Kim; Myoung-Hwan Park; Vincent M Rotello
Journal:  Nanomedicine (Lond)       Date:  2016-05-13       Impact factor: 5.307

Review 8.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

9.  The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.

Authors:  Eric Lau; Yongmei Feng; Giuseppina Claps; Michiko N Fukuda; Ally Perlina; Dylan Donn; Lucia Jilaveanu; Harriet Kluger; Hudson H Freeze; Ze'ev A Ronai
Journal:  Sci Signal       Date:  2015-12-08       Impact factor: 8.192

10.  Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.

Authors:  David Taggart; Tereza Andreou; Karen J Scott; Jennifer Williams; Nora Rippaus; Rebecca J Brownlie; Elizabeth J Ilett; Robert J Salmond; Alan Melcher; Mihaela Lorger
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.